Lebrikizumab, an IL-13 inhibitor for asthma, improved lung function but not clinical outcomes
www.pulmccm.org
Asthma's complex and protean inflammatory processes vary between individuals, some of whom have elevated levels of interleukin-13 despite maximal treatment with inhaled steroids. IL-13 prompts airway epithelial cells to secrete periostin, which acts on fibroblasts and may contribute to airway remodeling in asthma. Lebrikizumab is a monoclonal antibody inhibiting IL-13.
Lebrikizumab, an IL-13 inhibitor for asthma, improved lung function but not clinical outcomes
Lebrikizumab, an IL-13 inhibitor for asthma…
Lebrikizumab, an IL-13 inhibitor for asthma, improved lung function but not clinical outcomes
Asthma's complex and protean inflammatory processes vary between individuals, some of whom have elevated levels of interleukin-13 despite maximal treatment with inhaled steroids. IL-13 prompts airway epithelial cells to secrete periostin, which acts on fibroblasts and may contribute to airway remodeling in asthma. Lebrikizumab is a monoclonal antibody inhibiting IL-13.